echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Ann Intern Med: Mortality and morbidity in mild primary hyperparathyroidism

    Ann Intern Med: Mortality and morbidity in mild primary hyperparathyroidism

    • Last Update: 2022-05-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Primary hyperparathyroidism (PHPT) is a common endocrine disorder associated with increased risk and increased mortality from fractures, cardiovascular disease, kidney disease, and cancer


    Blood vessel

    Recently, a research article was published in Annals of Internal Medicine, an authoritative journal of internal medicine, to investigate the effect of PTX on mortality (primary endpoint) and key morbidity (secondary endpoint) in mild PHPT


    This prospective randomized controlled trial (ClinicalTrials.


    After 10 years, 15 patients had died (8 in the PTX group and 7 in the OBS group)


    cardiovascular events

    CONCLUSIONS: Parathyroidectomy does not appear to reduce morbidity or mortality in patients with mild PHPT


    Parathyroidectomy does not appear to reduce morbidity or mortality in patients with mild PHPT


    Original source:

    Mikkel Pretorius, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.